Showing 13 of 33 recruiting trials for “obsolete-primary-peritoneal-serouspapillary-carcinoma”
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
👨⚕️ Robert W. Holloway, MD, AdventHealth Cancer Institute📍 31 sites📅 Started Aug 2022View details ↗
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)
👨⚕️ Kara Long Roche, MD, Memorial Sloan Kettering Cancer Center📍 7 sites📅 Started Jun 2022View details ↗
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer
RecruitingNCT05129969 ↗
Registry Platform Ovarian and Endometrial Cancer
Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma
RecruitingNCT04314401 ↗
National Cancer Institute "Cancer Moonshot Biobank"
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)
👨⚕️ Tingyan Shi, M.D., Ph.D., Shanghai Gynecologic Oncology Group📍 5 sites📅 Started Oct 2019View details ↗
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
RecruitingNCT00488878 ↗
Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors
← PreviousPage 2 of 2
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →